This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Unit for Hours:H

Unit for Minutes: M

Loading text: $loading

Filter redirection page URL: /en-ie/events/

Login overlay needed?:

Filter Tags:All Medical indications|All Products|All Therapy Area

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Area

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successful

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successful

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Show More Naivagation Values: 10|25|50

Previous Text label: Previous

Next Text label: Next

Show Text label: Show:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Not provided

Register and get started
Access free resources

Access free resources

Order resources to support your patients including, samples, demo devices, leaflets plus more.

See what’s available
Educational webinars

Educational webinars

Join your peers and healthcare experts at exclusive events and webinar run by GSK

What’s coming up?
register for supply and product updates

Webinars On Demand

Catch up on select Asthma & COPD video webinars anytime from the comfort of your own office

Explore more
GSK respiratory products

GSK Respiratory

See the products in our Ellipta portfolio and find out how these can support you in treating your patients with Asthma and COPD.

Tivicay + Lamivudine

Tivicay▼+ Lamivudine

For your HIV treatment-naïve adult patients, the next step in the 2-drug regimen era.

Learn more

Tivicay▼ (dolutegravir) Prescribing information

Epivir (lamivudine) Prescribing information

Explore Bexsero - Meningococcal Group B Vaccine

Bexsero is indicated for the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease(IMD) caused by Neisseria meningitidis group B.

Learn more

Prescribing information

Using dual therapy or triple therapy for your patients?

The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI).1

Explore the IMPACT data

Prescribing information

GSK Registration

Stay Informed

Sign up to receive email alerts from GSK including important supply updates, new product information and events we are running.

Register Now
Chat Icon

Click-To-Chat


Connect with a member from the GSK Medical Information team using our LiveChat Service.

Click here

 

GSK Registration

Explore important updates

With our GSK Updates feature, you can access timely & relevant industry and product updates anytime you want, wherever you are.

Explore GSK Updates

Products

Information about our products including dosing and safety

See our products

Resources

Materials to support you in the treatment of your patients

View resources

GSK Updates

Stay up to date with relevant industry and product news

Explore updates

Events

Sign-up to attend webinars and events that we are running

Go to events

Abbreviations

FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References:

  1. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.